With the increasing prevalence of Crohn's disease (CD), treatment options for patients who fail conventional and advanced therapy are highly needed. Therefore, we explored the safety and efficacy of extracorporeal photopheresis (ECP) using 5-aminolevulinic acid (ALA) and blue light (405 nm). Patients with active CD who failed or were intolerant to biological therapy were eligible.
View Article and Find Full Text PDFPhotodynamic therapy (PDT) using 5-aminolevulinic acid (ALA) which is the precursor of the photosensitizer protoporphyrin IX (PpIX) is an available treatment for several diseases. ALA-PDT induces the apoptosis and necrosis of target lesions. We have recently reported the effects of ALA-PDT on cytokines and exosomes of human healthy peripheral blood mononuclear cells (PBMCs).
View Article and Find Full Text PDFPhotodynamic therapy (PDT) with 5-aminolevulinic acid (ALA), a precursor to the potent photosensitizer, protoporphyrin IX (PpIX), is an established modality for several malignant and premalignant diseases. This treatment is based on the light-activated PpIX in targeted lesions. Although numerous studies have confirmed the necrosis and apoptosis involved in the mechanism of action of this modality, little information is available for the change of exosome levels after treatment.
View Article and Find Full Text PDFTidsskr Nor Laegeforen
January 2011
Background: It is likely that improved treatment of diabetes during the last decades has led to a declining prevalence of retinopathy. We have assessed whether this is the case for patients with type I diabetes.
Material And Methods: Medical records were retrospectively reviewed for all patients who were diagnosed with type 1 diabetes in the periods 1960-1975 (early group) and 1985-1990 (late group) at the diabetes clinic in St.